|
|
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL
Second Department of Internal Medicine (K.I., M.Mu., T.N., T.I., N.M., E.U., K.H.) and Department of Pharmacology (S.T., N.I., D.J., M.Mi.), Osaka Medical College, Takatsuki City, Osaka, Japan
Received for publication
September 21, 2007
Accepted
November 15, 2007.
| Abstract |
|---|
|
|
|---|
Chymase is a chymotrypsin-like serine protease located in the secretory granules of mast cells. Serine proteases, such as MMP-3, and trypsin are known to process promatrix metalloproteinase (proMMP)-9 to MMP-9 in vitro (Sang et al., 1995
; Shapiro et al., 1995
). Fang et al. (1996
, 1997
) reported that chymase can also convert proMMP-9 to MMP-9 in vitro. A recent article demonstrated that the conversion of proMMP-9 to MMP-9 in media from peritoneal cell cultures was significantly attenuated in chymase-deficient mice compared with wild-type mice (Tchougounova et al., 2005
). However, whether chymase is involved in MMP-9 activation in colitis tissues has remained unclear.
The present study clarified whether chymase contributes to MMP-9 activation in colitis tissues in DSS-treated mice in vitro. Furthermore, we evaluated the effects of administering chymase inhibitor on the development of colitis in vivo.
| Materials and Methods |
|---|
|
|
|---|
Animal Treatment. Six-week-old male BALB/c mice were obtained from Japan SLC (Shizuoka, Japan). Mice were fed with regular mouse chow and were housed in a temperature-, humidity-, and light-controlled room. A mouse experimental model of colitis was induced using DSS in accordance with previous reports (Hirata et al., 2007
; Inoue et al., 2007
). For normal mice, each mouse was allowed ad libitum access to tap water for 7 days. For DSS-treated mice, each animal was allowed ad libitum access to 5% DSS solution, supplied as drinking water, for 7 days. To investigate the effect of chymase inhibitor, each mouse was intraperitoneally administered NK3201 (10 mg/kg per once a day) or placebo immediately after the start of DSS treatment. Experimental procedures for animals were conducted in accordance with the guidelines of Osaka Medical College.
Tissue Extract. Intestine was homogenized in 20 mM sodium phosphate buffer (pH 7.4) and separated by centrifugation at 10,000 rpm for 30 min. The supernatant was discarded, and then the pellet was resuspended and homogenized in 10 mM sodium phosphate buffer (pH 7.4) containing 2 M KCl and 0.1% Nonidet P-40. The homogenate was centrifuged at 10,000 rpm for 30 min, and then enzyme activities were measured in the supernatant.
Chymase Activity. Chymase activity was measured by incubating tissue extracts for 1 h at 37°C with 5 mM Suc-Ala-Ala-Pro-Phe-4-methylcoumaryl-7-amide (Peptide Institute, Osaka, Japan) as a substrate for the measurement of chymase activity in 100 mM Tris-HCl buffer (pH 8.5) containing 200 mM NaCl (Kirimura et al., 2005
). The enzyme reaction was terminated by the addition of 3% metaphosphoric acid. After centrifugation of the mixture, 7-amino-4-methylcoumarin was measured by fluorophotometry (excitation, 380 nm; emission, 460 nm). One unit of chymase activity was defined as the amount of enzyme cleaving 1 µmol of 7-amino-4methylcoumarin/min. Protein concentration was assayed with BCA protein assay reagents (Pierce, Rockford, IL) using bovine serum albumin as a standard.
Gelatin Zymography. Equal volumes of tissue extract (80 µgof protein) were resolved by electrophoresis on 10% SDS-polyacrylamide gels containing 1 mg/ml gelatin (Furubayashi et al., 2007
). Thereafter, gels were renatured in 50 mM Tris-HCl (pH 7.5) containing 100 mM NaCl and 2.5% Triton X-100 for 90 min to remove SDS and then incubated with 50 mM Tris-HCl (pH 7.5) containing 10 mM CaCl2 for 48 h. Gels were stained with Coomassie Brilliant Blue, and gelatinolytic activity was quantified using NIH Image1.61 software.
Effect of Chymase Inhibitor on MMP-9 Activation in Extracts of Colitis Tissues. To investigate whether chymase could cleave proMMP-9 to MMP-9 in colitis, tissues from mice treated with DSS for 7 days were incubated for 8 h at 37°C before gelatin zymography. The effect of chymase inhibition was also examined after incubation with 1 µM of the specific chymase inhibitor, NK3201, for 8 h at 37°C.
Evaluation of Colitis. Disease activity index (DAI) was determined by two investigators blinded to the protocol by scoring the extent of body weight loss, stool consistency, and the presence of occult/gross bleeding in accordance with the method described by Murthy et al. (1993
). In brief, no weight loss was considered as 0, weight loss of 1 to 5% was scored as 1, loss of 5 to 10% was scored as 2, loss of 10 to 15% was scored as 3, and loss of >15% was scored as 4. Stools were characterized as normal (score 0), pasty stools not sticking to the anus (score 2), or liquid stools sticking to the anus (score 4). For occult blood, no blood was scored as 0, positive occult blood was scored as 2, and gross bleeding was scored as 4. Total value of these scores was divided by three and was regarded as DAI ranging from 0 to 4. After inducing anesthesia with sodium pentobarbital (50 mg/kg i.p.), the large intestine was removed for measurement of intestine length and evaluation of intestinal shortening (Hirata et al., 2007
).
Histological Evaluation. For histological damage score (HDS), the rectum was fixed in 10% neutral buffered formalin, and specimens (4-mm thick) were stained using hematoxylin and eosin. Randomly selected fields (n = 8) magnified 100-fold in each section were inspected and blindly graded by a pathologist using the protocol described by Murthy et al. (1993
). In brief, normal colonic mucosa was considered as 0, loss of the bottom one-third of crypts was graded as 1, loss of the bottom two-thirds of crypts was graded as 2, loss of the entire crypt area with surface epithelium remaining intact was graded as 3, and loss of both the entire crypt area and surface epithelium (erosion) was graded as 4.
To elucidate the inflammatory process, neutrophils were immunostained with rat anti-mouse neutrophil antibody (Serotec Ltd., Oxfordshire, UK) (Furubayashi et al., 2007
). The number of neutrophils was determined, using the computerized morphometry system, and was expressed as the number of stained cells per millimeter squared.
Statistical Analysis. Data are expressed as mean ± S.E.M. Significant differences between mean values of the two groups were evaluated using Student's t test for unpaired data. Significant differences among mean values for multiple groups were evaluated using one-way analysis of variance followed by Fisher's test. Values of P < 0.05 were considered statistically significant.
| Results |
|---|
|
|
|---|
|
Effect of Chymase Inhibitor on MMP-9 Activation in Colitis Tissue Extracts. Zymography showed that the MMP-9 band in colitis tissues from DSS-treated mice was significantly thinner with an 8-h incubation at 37°C than with nonincubation (Fig. 2A). Density of the MMP-9 band was significantly denser in the presence of a chymase inhibitor NK3201 at 37°C than in the absence and was the same as that seen with nonincubation (Fig. 2B).
|
|
Histological Evaluation. Figure 4A shows typical photographs of the rectum from placebo- and NK3201-treated mice. HDS for the rectum was 1.48 ± 0.20 in the placebo-treated group and 0.80 ± 0.23 in the NK3201-treated group, representing a significant difference (Fig. 4B).
|
|
|
| Discussion |
|---|
|
|
|---|
To clarify the second issue, we evaluated the effect of chymase inhibitor NK3201 on the development of colitis induced by DSS in mice. As in our previous model (Hirata et al., 2007
; Inoue et al., 2007
), DAI was markedly increased 7 days after the start of DSS treatment in the present study, although DAI was 0 in all normal mice. In the placebo-treated group, body weight loss, liquid stools, and the presence of occult blood in stool or gross bleeding were observed in all mice. However, significant improvements in all parameters were observed in the NK3201-treated group, resulting in significantly reduced DAI score. Although we have observed intestinal shortening caused by intestinal inflammation in previous studies (Hirata et al., 2007
; Inoue et al., 2007
), the colon was significantly longer in the NK3201-treated group than in the placebo-treated group. HDS was improved in the NK3201-treated group compared with the placebo-treated group, and the infiltrated neutrophil number was also decreased in the NK3201-treated group. All of these findings strongly suggest that chymase inhibition might offer a useful strategy for preventing the development of colitis.
MMP-9 is involved in degradation and remodeling of the ECM and is thus involved not only in the pathogenesis of several inflammatory diseases, such as colitis, but also aneurysm. For example, MMP-9 expression is associated with the development of aortic aneurysms following elastic fiber disruption (Thompson et al., 1995
). Moreover, targeted gene disruption of MMP-9 suppresses the development of aortic aneurysm in mice (Pyo et al., 2000
). We recently demonstrated that NK3201 significantly prevents the progression of abdominal aortic aneurysm in dogs (Furubayashi et al., 2007
). In the dog aneurismal model, both chymase and MMP-9 activities were significantly increased in aneurismal aortas, but NK3201 significantly attenuated not only chymase activity but also MMP-9 activity. Chymase can also convert proMMP-9 to MMP-9 in vitro (Fang et al., 1996
, 1997
). Thus, the mechanism by which chymase inhibitor prevents aortic aneurysm might be thought to inhibit MMP-9 activation, but we have not confirmed whether chymase inhibition could inhibit MMP-9 activation in tissues of aneurismal aorta. In the present study, MMP-9 activity in colitis tissues from DSS-treated mice was significantly higher after incubation for 8 h than nonincubation; this suggests that the extract included proMMP-9-activating enzymes. However, the incubated samples to which a specific chymase inhibitor, NK3201, was applied had significantly attenuated the MMP-9 activity. Thus, we confirmed the importance of chymase-dependent MMP-9 activation in colitis tissues in vitro. Furthermore, MMP-9 level was significantly decreased by treatment with NK3201, whereas proMMP-9 level tended to be increased (placebo-treated group, 100 ± 6.6%; NK3201-treated group, 109.5 ± 7.9%). This finding suggests that chymase inhibition might induce the accumulation of proMMP-9 by inhibiting the conversion of proMMP-9 to MMP-9. The mechanism by which chymase inhibitor prevents the development of colitis might thus depend on the inhibition of MMP-9 activation in colitis tissues.
MMP-9 is abundantly expressed in the colonic tissues of patients with ulcerative colitis compared with controls (Baugh et al., 1999
). In mouse DSS-induced colitis, a significant increase in MMP-9 activity has been observed, as observed in the present study (Castaneda et al., 2005
; Santana et al., 2006
). In MMP-9-deficient mice, loss of body weight, diarrhea, and fecal blood after DSS treatment was significantly improved compared with control mice (Castaneda et al., 2005
). Thus, MMP-9 inhibition may represent a useful strategy for preventing the development of colitis. Although NK3201 could not inhibit MMP-9 activity (data not shown), this inhibitor could indirectly reduce MMP-9 activity in vivo and might result in the same effect as direct inhibition of MMP-9 activity.
Mast cells contain various chemical mediators, histamine, leukotriene, and platelet-activating factor, all of which play important roles in acute and chronic tissue injury (Matsuo et al., 2003
; Barbara et al., 2006
). Mast cells may play an important role in the pathogenesis of IBD (McAuley and Sommers, 1961
). For example, mast cell infiltration is increased in the colonic mucosa of active IBD (Nishida et al., 2002
). Iba et al. (2002
) reported that mast cell numbers in the rectum were significantly increased after DSS treatment in rats. In mast cell-deficient mice, macroscopic colonic damage was significantly suppressed compared with control mice after DSS treatment (Araki et al., 2000
). Chymase is located in mast cell granules, and the mechanisms underlying reduced colonic damage in mast cell-deficient mice may include suppression of chymase levels.
In conclusion, we demonstrated the importance of chymase-dependent MMP-9 activation in colitis tissues in DSS-treated mice in vitro and the usefulness of chymase inhibition for preventing the development of colitis via inhibition of MMP-9 activation in vivo.
| Footnotes |
|---|
ABBREVIATIONS: IBD, inflammatory bowel disease; DAI, disease activity index; DSS, dextran sodium sulfate; ECM, extracellular matrix; HDS, histological damage score; MMP, matrix metalloproteinase; NK3201, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[{3,4-dioxo-1-phenyl-7-(2-pyridyloxy)}-2-heptyl] acetamide; proMMP, promatrix metalloproteinase.
Address correspondence to: Dr. Shinji Takai, Department of Pharmacology, Osaka Medical College, Takatsuki City, Osaka 569-8686, Japan. E-mail: pha010{at}art.osaka-med.ac.jp
| References |
|---|
|
|
|---|
Araki Y, Andoh A, Fujiyama Y, and Bamba T (2000) Development of dextran sulphate sodium-induced experimental colitis is suppressed in genetically mast cell-deficient Ws/Ws rats. Clin Exp Immunol 119: 264–269.[CrossRef][Medline]
Barbara G, Stanghellini V, De Giorgio R, and Corinaldesi R (2006) Functional gastrointestinal disorders and mast cells: implications for therapy. Neurogastroenterol Motil 18: 6–17.[CrossRef][Medline]
Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, Taylor CJ, and Evans GS (1999) Matrix metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology 117: 814–822.[CrossRef][Medline]
Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, Rojas M, Wang L, Oprea G, Garg P, et al. (2005) Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 129: 1991–2008.[CrossRef][Medline]
Elson CO, Sartor RB, Tennyson GS, and Riddell RH (1995) Experimental models of inflammatory bowel disease. Gastroenterology 109: 1344–1367.[CrossRef][Medline]
Fang KC, Raymond WW, Blount JL, and Caughey GH (1997) Dog mast cell
-chymase activates progelatinase B by cleaving the Phe88-Gln89 and Phe91-Glu92 bonds of the catalytic domain. J Biol Chem 272: 25628–25635.
Fang KC, Raymond WW, Lazarus SC, and Caughey GH (1996) Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase. J Clin Invest 97: 1589–1596.[Medline]
Furubayashi K, Takai S, Jin D, Muramatsu M, Ibaraki T, Nishimoto M, Fukumoto H, Katsumata T, and Miyazaki M (2007) The significance of chymase in the progression of abdominal aortic aneurysms in dogs. Hypertens Res 30: 349–357.[CrossRef][Medline]
Garg P, Rojas M, Ravi A, Bockbrader K, Epstein S, Vijay-Kumar M, Gewirtz AT, Merlin D, and Sitaraman SV (2006) Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis. J Immunol 77: 4103–4112.
Hirata I, Yasumoto S, Toshina K, Inoue T, Nishikawa T, Murano N, Murano M, Wang FY, and Katsu K (2007) Evaluation of the effect of pyrrolidine dithiocarbamate in suppressing inflammation in mice with dextran sodium sulfate-induced colitis. World J Gastroenterol 13: 1666–1671.[Medline]
Iba Y, Sugimoto Y, and Kamei C (2002) Participation of mast cells in colitis inflammation induced by dextran sulfate sodium. Methods Find Exp Clin Pharmacol 24: 15–18.[CrossRef][Medline]
Inoue T, Murano M, Abe Y, Morita E, Murano N, Yasumoto S, Toshina K, Nishikawa T, Maemura K, Hirata I, et al. (2007) Therapeutic effect of nimesulide on colorectal carcinogenesis in experimental murine ulcerative colitis. J Gastroenterol Hepatol 22: 1474–1481.[CrossRef][Medline]
Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, Nakabayashi M, Mino Y, and Miyazaki M (2005) Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 28: 457–464.[CrossRef][Medline]
Matsuo T, Ikura Y, Ohsawa M, Ogami M, Kayo S, Yoshimi N, Hai E, Naruko T, Ohishi M, Higuchi K, et al. (2003) Mast cell chymase expression in Helicobacter pylori-associated gastritis. Histopathology 43: 538–549.[CrossRef][Medline]
McAuley RL and Sommers SC (1961) Mast cells in nonspecific ulcerative colitis. Am J Dig Dis 6: 233–236.[CrossRef]
Medina C and Radomski MW (2006) Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 318: 933–938.
Murthy SN, Cooper HS, Shim H, Shah RS, Ibrahim SA, and Sedergran DJ (1993) Treatment of dextran sulfate sodium-induced murine colitis by intracolonic cyclosporin. Dig Dis Sci 38: 1722–1734.[CrossRef][Medline]
Nishida Y, Murase K, Isomoto H, Furusu H, Mizuta Y, Riddell RH, and Kohno S (2002) Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 49: 678–682.[Medline]
Pyo R, Lee JK, Shipley JM, Curci JA, Mao D, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, and Thompson RW (2000) Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 105: 1641–1649.[Medline]
Sang QX, Birkedal-Hansen H, and Van Wart HE (1995) Proteolytic and non-proteolytic activation of human neutrophil progelatinase B. Biochim Biophys Acta 1251: 99–108.[CrossRef][Medline]
Santana A, Medina C, Paz-Cabrera MC, Diaz-Gonzalez F, Farre E, Salas A, Radomski MW, and Quintero E (2006) Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol 12: 6464–6472.[Medline]
Shapiro SD, Fliszar CJ, Broekelmann TJ, Mecham RP, Senior RM, and Welgus HG (1995) Activation of the 92-kDa gelatinase by stromelysin and 4-aminophenylmercuric acetate. Differential processing and stabilization of the carboxyl-terminal domain by tissue inhibitor of metalloproteinases (TIMP). J Biol Chem 270: 6351–6356.
Takai S, Jin D, Nishimoto M, Yuda A, Sakaguchi M, Kamoshita K, Ishida K, Sukenaga Y, Sasaki S, and Miyazaki M (2001) Oral administration of a specific chymase inhibitor, NK3201, inhibits vascular proliferation in grafted vein. Life Sci 69: 1725–1732.[CrossRef][Medline]
Takai S and Miyazaki M (2003) Application of a chymase inhibitor, NK3201, for prevention of vascular proliferation. Cardiovasc Drug Rev 21: 185–198.[Medline]
Tarlton JF, Whiting CV, Tunmore D, Bregenholt S, Reimann J, Claesson MH, and Bland PW (2000) The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a murine model of colitis. Am J Pathol 157: 1927–1935.
Tchougounova E, Lundequist A, Fajardo I, Winberg JO, Abrink M, and Pejler G (2005) A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 280: 9291–9296.
Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mecham RP, Welgus HG, and Parks WC (1995) Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 96: 318–326.[Medline]
Tsunemi K, Takai S, Nishimoto M, Jin D, Sakaguchi M, Muramatsu M, Yuda A, Sasaki S, and Miyazaki M (2004) A specific chymase inhibitor, 2-(5-formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-[[3,4-dioxo-1-phenyl-7-(2-pyridyloxy)]-2-heptyl]acetamide (NK3201), suppresses development of abdominal aortic aneurysm in hamsters. J Pharmacol Exp Ther 309: 879–883.
This article has been cited by other articles:
![]() |
C. Matsumoto, T. Hayashi, K. Kitada, C. Yamashita, M. Miyamura, T. Mori, A. Ukimura, M. Ohkita, D. Jin, S. Takai, et al. Chymase Plays an Important Role in Left Ventricular Remodeling Induced by Intermittent Hypoxia in Mice Hypertension, July 1, 2009; 54(1): 164 - 171. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Garg, M. Vijay-Kumar, L. Wang, A. T. Gewirtz, D. Merlin, and S. V. Sitaraman Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis Am J Physiol Gastrointest Liver Physiol, February 1, 2009; 296(2): G175 - G184. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||